Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
ATRX-Deficient Glioma Sensitivity to RTK/PDGFR Inhibitors Ex
2026-04-30
This study demonstrates that high-grade glioma cells lacking ATRX are significantly more sensitive to multi-targeted RTK and PDGFR inhibitors. These findings highlight ATRX status as a critical biomarker for therapeutic response and future clinical trial design in glioblastoma.
-
ApexPrep DNA Plasmid Miniprep Kit: Precision for Molecular B
2026-04-29
The ApexPrep DNA Plasmid Miniprep Kit delivers high-yield, molecular biology grade plasmid DNA extraction, empowering workflows from advanced cloning to complex leukemia research. Its robust buffer system and streamlined protocol ensure reproducible results and exceptional purity for the most demanding downstream applications.
-
FGF4-FGFR1 Axis Preserves Podocyte Survival in Diabetic Kidn
2026-04-29
This study reveals that podocyte-secreted FGF4 is a critical regulator of glomerular barrier integrity and function in diabetic kidney disease (DKD). The authors demonstrate that activating FGF4-FGFR1 signaling mitigates podocyte loss and renal injury by engaging the AMPK-FOXO1 axis, suggesting new therapeutic directions for DKD beyond current angiotensin II receptor antagonist strategies.
-
NADH Redox Dynamics: Strategic Frontiers in Translational Re
2026-04-28
Explore the mechanistic underpinnings and translational applications of NADH (Reduced-form Nicotinamide Adenine Dinucleotide) in metabolic disease and cancer research. This thought-leadership article offers actionable insights for researchers, drawing on emerging evidence for NADH’s roles in cellular energy metabolism, redox balance, and advanced therapeutic strategies.
-
Lactate Drives HMGB1 Modification and Exosomal Release in Se
2026-04-28
This study reveals that lactate not only serves as a biomarker but also actively promotes HMGB1 lactylation, acetylation, and its exosomal release from macrophages during polymicrobial sepsis. These findings highlight a previously unrecognized role of lactate in amplifying inflammatory signaling, suggesting potential therapeutic targets for modulating sepsis severity.
-
Biotin Azide: Precision Biotinylation for Click Chemistry As
2026-04-27
Biotin Azide, supplied by APExBIO, enables rapid, selective labeling of alkynylated biomolecules through copper-catalyzed click chemistry, driving robust affinity purification and high-sensitivity detection. This article offers evidence-based protocol enhancements, troubleshooting strategies, and translational insights from cutting-edge cholesterol signaling research.
-
PNU 74654: Precision Wnt Pathway Inhibition in Muscle and Ca
2026-04-27
Explore the advanced use of PNU 74654, a leading Wnt signaling pathway inhibitor, in dissecting cell fate decisions within muscle and cancer biology. This article uniquely focuses on protocol optimization and mechanistic insights for high-impact research.
-
Myriocin: Serine Palmitoyltransferase Inhibitor in Research
2026-04-26
Myriocin empowers precise manipulation of sphingolipid metabolism, enabling robust in vitro and in vivo assays for oncology, immunology, and cardiovascular studies. This article delivers actionable workflows, troubleshooting insights, and reference-driven innovations to maximize data reliability when using this selective serine palmitoyltransferase inhibitor.
-
Erastin: Precision Ferroptosis Inducer for Cancer Biology Re
2026-04-25
Erastin, supplied by APExBIO, sets the gold standard for selective ferroptosis induction in RAS/BRAF-mutant cancer models. Its robust, quantifiable workflow enables researchers to dissect oxidative stress vulnerabilities and optimize cancer therapy studies with reproducible precision.
-
Lipo3K Transfection Reagent: Optimizing Gene Delivery in Com
2026-04-24
Lipo3K Transfection Reagent stands out for its high efficiency and low cytotoxicity, particularly in challenging cell types and co-transfection applications. This guide unpacks experimental strategies, troubleshooting, and protocol enhancements that set Lipo3K apart for advanced gene expression and RNA interference research.
-
Inhibition of Renal OCT2/MATE1 by 5-HT3 Antagonists: Palonos
2026-04-24
This study systematically quantifies how 5-HT3 receptor antagonists—including palonosetron—interfere with renal drug secretion by inhibiting OCT2 and MATE1 transporters in vitro. These findings inform cancer research and antiemetic drug development by revealing potential drug-drug interaction pathways and highlighting the importance of transporter profiling in preclinical workflows.
-
CLK2 Drives Platinum Resistance in Ovarian Cancer via BRCA1
2026-04-23
This study uncovers Cdc2-like kinase 2 (CLK2) as a key driver of platinum resistance in ovarian cancer by promoting enhanced DNA repair through phosphorylation of BRCA1 at Ser1423. These insights offer new mechanistic targets for overcoming chemotherapy resistance and support the rationale for DNA damage response assays in experimental oncology.
-
Lipo3K Transfection Reagent: High-Efficiency Lipid Delivery
2026-04-23
Lipo3K Transfection Reagent enables high-efficiency delivery of nucleic acids into even difficult-to-transfect cells, offering lower cytotoxicity than legacy reagents. As a cationic lipid transfection reagent, it supports robust gene expression and RNA interference research in serum-containing media.
-
ABT-263 (Navitoclax): Senolytics Beyond Apoptosis Assays
2026-04-22
Explore the unique senolytic and neuroinflammatory insights of ABT-263 (Navitoclax) in cancer biology and aging research. Learn how this oral Bcl-2 inhibitor extends beyond standard apoptosis assays, with evidence from pivotal studies and practical protocol guidance.
-
Liproxstatin-1 HCl: Precision Ferroptosis Control via Mitoch
2026-04-22
Explore how Liproxstatin-1 HCl enables nuanced, mitochondria-informed ferroptosis control in cell and organ injury models. This article offers an advanced analysis, drawing on new mechanistic insights to guide ferroptosis assay design and translational research.